Patients Need ZOMETA® To Prevent Destruction and Skeletal–Related Events in Breast Cancer Patients
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Breast Cancer Patient Case Study - Marta Marta N.
  • Aged 57 years
  • Math teacher
  • Grandmother of 2
Page  1 2 3 4


The vicious cycle of bone destruction is ongoing in patients like Marta


  • Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction8,9

Because bone is constantly being attacked even when the primary tumour is in remission, ZOMETA® must be dosed every 3 to 4 weeks8,10




Because bone is constantly being attacked even when the primary tumour is in remission, ZOMETA must be dosed every 3 to 4 weeks8,10





Page  1 2 3 4